Clinical Trial Transparency: A Reassessment of Industry Compliance With Clinical Trial Registration and Reporting Requirements in the United States
December 13th, 2017
Scott Lassman co-authored the article, "Clinical Trial Transparency: a Reassessment of Industry Compliance With Clinical Trial Registration and Reporting Requirements in the United States," BMJ Open, Volume 7, Issue 9 (2017). The article analyzes compliance with clinical trial disclosure laws in the U.S.
Categories: Publications
Criticism of FDA Citizen Petitions is Often Misguided
November 21st, 2017
Scott Lassman evaluates criticism of the FDA citizen petition process in his article, "Criticism of FDA Citizen Petitions is Often Misguided," Law360, November 20, 2017.
Categories: Publications
Scott Lassman
Scott Lassman has more than 30 years’ experience in FDA law and policy, both as an in-house attorney and in private practice. He provides strategic advice and advocacy to small, mid-size and large pharmaceutical, biotechnology and medical device companies, as well as the trade associations that represent them and the investors who fund them. His practice covers all aspects of FDA regulatory law, with a special focus on exclusivity, biosimilars, product approval and policy matters...
For More Information
